{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:40:13Z","timestamp":1793817613714,"version":"4.6.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073143"],"award-info":[{"award-number":["82073143"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2021YFC2009100\uff0c2021YFC2009105"],"award-info":[{"award-number":["2021YFC2009100\uff0c2021YFC2009105"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Endogenous nitric oxide (NO) produced by nitric oxide synthases (NOSs) plays an important immunosuppressive role in the tumor microenvironment. In melanoma, NOS1 expression increases with tumor progression and correlates with tumor immune escape through the inhibition of type I interferon (IFN) signaling. However, the immune regulatory role and related mechanisms of NOS1, as well as its impacts on immune therapies such as immune checkpoint blockade (ICB) in melanoma, remain unclear. Here, we found that NOS1 expression induces IRF7 modification by S-nitrosylation at the C435 site in mice (C481 in humans), which functionally promoted tumor growth in mouse models. Mechanistically, IRF7-C435-SNO inhibited IFN\u03b2 transcription under PRR signal activation, leading to a disorder in the initiation of the type I interferon response in melanoma cells. In a melanoma mouse model, IRF7-C435-SNO decreased the infiltration and activation of CD8\u2009+\u2009T cells in the tumor microenvironment by reducing antigen presentation processes in tumor cells and inhibiting the maturation of DC1. Clinically, high expression of NOS1 correlated with poor survival prognosis and resistance to ICB anti-tumor therapies in melanoma cases with less immune cell infiltration. Our study suggests that NOS1 expression in melanoma characterizes IFN-I signal disorders in response to innate immune stimulation through IRF7 s-nitrosylation. Targeting NOS1 signaling might be beneficial for overcoming immune therapeutically resistance, particularly in immune-cold melanoma phenotype.<\/jats:p>","DOI":"10.1038\/s41419-025-08201-y","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T15:25:43Z","timestamp":1768404343000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["S-nitrosylation of IRF7 induced by NOS1 expression in melanoma suppresses anti-tumor immunity"],"prefix":"10.1038","volume":"17","author":[{"given":"Yuxin","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisi","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minzhu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqiu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangyan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingqun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingtao","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0478-6376","authenticated-orcid":false,"given":"Qiuzhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"8201_CR1","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","volume":"175","author":"L Jerby-Arnon","year":"2018","unstructured":"Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, et al. A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. Cell. 2018;175:984\u201397.e24.","journal-title":"Cell"},{"key":"8201_CR2","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375:819\u201329.","journal-title":"N Engl J Med"},{"key":"8201_CR3","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41591-021-01331-8","volume":"27","author":"D Liu","year":"2021","unstructured":"Liu D, Lin JR, Robitschek EJ, Kasumova GG, Heyde A, Shi A, et al. Evolution of delayed resistance to immunotherapy in a melanoma responder. Nat Med. 2021;27:985\u201392.","journal-title":"Nat Med"},{"key":"8201_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","volume":"20","author":"A Kalbasi","year":"2020","unstructured":"Kalbasi A, Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol. 2020;20:25\u201339.","journal-title":"Nat Rev Immunol"},{"key":"8201_CR5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity. Nature. 2015;523:231\u20135.","journal-title":"Nature"},{"key":"8201_CR6","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1084\/jem.20051848","volume":"203","author":"H Sumimoto","year":"2006","unstructured":"Sumimoto H, Imabayashi F, Iwata T, Kawakami Y. The BRAF\u2013MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med. 2006;203:1651\u20136.","journal-title":"J Exp Med"},{"key":"8201_CR7","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ccell.2019.08.008","volume":"36","author":"ML Burr","year":"2019","unstructured":"Burr ML, Sparbier CE, Chan KL, Chan YC, Kersbergen A, Lam EYN, et al. An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer. Cancer Cell. 2019;36:385\u2013401.e8.","journal-title":"Cancer Cell"},{"key":"8201_CR8","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aar3342","volume":"10","author":"SJ Rodig","year":"2018","unstructured":"Rodig SJ, Gusenleitner D, Jackson DG, Gjini E, Giobbie-Hurder A, Jin C, et al. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Sci Transl Med. 2018;10:eaar3342.","journal-title":"Sci Transl Med"},{"key":"8201_CR9","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","volume":"25","author":"D Liu","year":"2019","unstructured":"Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Arnon L, et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat Med. 2019;25:1916\u201327.","journal-title":"Nat Med"},{"key":"8201_CR10","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.immuni.2021.10.020","volume":"55","author":"E Duong","year":"2022","unstructured":"Duong E, Fessenden TB, Lutz E, Dinter T, Yim L, Blatt S, et al. Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity. Immunity. 2022;55:308\u201323.e9.","journal-title":"Immunity"},{"key":"8201_CR11","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","volume":"21","author":"S Jhunjhunwala","year":"2021","unstructured":"Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat Rev Cancer. 2021;21:298\u2013312.","journal-title":"Nat Rev Cancer"},{"key":"8201_CR12","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nrc1910","volume":"6","author":"D Fukumura","year":"2006","unstructured":"Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nat Rev Cancer. 2006;6:521\u201334.","journal-title":"Nat Rev Cancer"},{"key":"8201_CR13","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/nature06778","volume":"452","author":"KH Lim","year":"2008","unstructured":"Lim KH, Ancrile BB, Kashatus DF, Counter CM. Tumour maintenance is mediated by eNOS. Nature. 2008;452:646\u20139.","journal-title":"Nature"},{"key":"8201_CR14","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1089\/ars.2018.7527","volume":"30","author":"V Somasundaram","year":"2019","unstructured":"Somasundaram V, Basudhar D, Bharadwaj G, No JH, Ridnour LA, Cheng RYS, et al. Molecular mechanisms of nitric oxide in cancer progression, signal transduction, and metabolism. Antioxidants Redox Signal. 2019;30:1124\u201343.","journal-title":"Antioxidants Redox Signal"},{"key":"8201_CR15","doi-asserted-by":"publisher","first-page":"6526","DOI":"10.1158\/0008-5472.CAN-13-1620","volume":"73","author":"Q Du","year":"2013","unstructured":"Du Q, Zhang X, Liu Q, Zhang X, Bartels CE, Geller DA. Nitric oxide production upregulates Wnt\/\u03b2-catenin signaling by inhibiting Dickkopf-1. Cancer Res. 2013;73:6526\u201337.","journal-title":"Cancer Res"},{"key":"8201_CR16","doi-asserted-by":"publisher","first-page":"806","DOI":"10.4049\/jimmunol.175.2.806","volume":"175","author":"R Morita","year":"2005","unstructured":"Morita R, Uchiyama T, Hori T. Nitric oxide inhibits IFN-\u03b1 production of human plasmacytoid dendritic cells partly via a guanosine 3\u2032,5\u2032-cyclic monophosphate-dependent pathway. J Immunol. 2005;175:806\u201312.","journal-title":"J Immunol"},{"key":"8201_CR17","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1084\/jem.20042028","volume":"201","author":"V Bronte","year":"2005","unstructured":"Bronte V, Kasic T, Gri G, Gallana K, Borsellino G, Marigo I, et al. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med. 2005;201:1257\u201368.","journal-title":"J Exp Med"},{"key":"8201_CR18","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nm1609","volume":"13","author":"S Nagaraj","year":"2007","unstructured":"Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med. 2007;13:828\u201335.","journal-title":"Nat Med"},{"key":"8201_CR19","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.3390\/cells10102655","volume":"10","author":"I Navasardyan","year":"2021","unstructured":"Navasardyan I, Bonavida B. Regulation of T cells in cancer by nitric oxide. Cells. 2021;10:2655.","journal-title":"Cells"},{"key":"8201_CR20","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.3390\/cancers15061755","volume":"15","author":"SK Garg","year":"2023","unstructured":"Garg SK, Sun J, Kim Y, Whiting J, Sarnaik A, Conejo-Garcia JR, et al. Dichotomous nitric oxide\u2013dependent post-translational modifications of STAT1 are associated with ipilimumab benefits in melanoma. Cancers. 2023;15:1755.","journal-title":"Cancers"},{"key":"8201_CR21","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/nri1961","volume":"6","author":"GP Dunn","year":"2006","unstructured":"Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol. 2006;6:836\u201348.","journal-title":"Nat Rev Immunol"},{"key":"8201_CR22","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1084\/jem.20101158","volume":"208","author":"MS Diamond","year":"2011","unstructured":"Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 2011;208:1989\u20132003.","journal-title":"J Exp Med"},{"key":"8201_CR23","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1084\/jem.20101159","volume":"208","author":"MB Fuertes","year":"2011","unstructured":"Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8\u03b1+ dendritic cells. J Exp Med. 2011;208:2005\u201316.","journal-title":"J Exp Med"},{"key":"8201_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/nri3133","volume":"12","author":"JM Gonz\u00e1lez-Navajas","year":"2012","unstructured":"Gonz\u00e1lez-Navajas JM, Lee J, David M, Raz E. Immunomodulatory functions of type I interferons. Nat Rev Immunol. 2012;12:125\u201335.","journal-title":"Nat Rev Immunol"},{"key":"8201_CR25","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nri3845","volume":"15","author":"L Zitvogel","year":"2015","unstructured":"Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol. 2015;15:405\u201314.","journal-title":"Nat Rev Immunol"},{"key":"8201_CR26","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.it.2015.01.002","volume":"36","author":"G Schreiber","year":"2015","unstructured":"Schreiber G, Piehler J. The molecular basis for functional plasticity in type I interferon signaling. Trends Immunol. 2015;36:139\u201349.","journal-title":"Trends Immunol"},{"key":"8201_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14970-0","volume":"7","author":"J Markowitz","year":"2017","unstructured":"Markowitz J, Wang J, Vangundy Z, You J, Yildiz V, Yu L, et al. Nitric oxide mediated inhibition of antigen presentation from DCs to CD4+ T cells in cancer and measurement of STAT1 nitration. Sci Rep. 2017;7:15424.","journal-title":"Sci Rep"},{"key":"8201_CR28","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1172\/JCI69611","volume":"124","author":"Q Liu","year":"2014","unstructured":"Liu Q, Tomei S, Ascierto ML, De Giorgi V, Bedognetti D, Dai C, et al. Melanoma NOS1 expression promotes dysfunctional IFN signaling. J Clin Invest. 2014;124:2147\u201359.","journal-title":"J Clin Invest"},{"key":"8201_CR29","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1186\/s13046-019-1448-9","volume":"38","author":"P Xu","year":"2019","unstructured":"Xu P, Ye S, Li K, Huang M, Wang Q, Zeng S, et al. NOS1 inhibits the interferon response of cancer cells by S-nitrosylation of HDAC2. J Exp Clin Cancer Res. 2019;38:483.","journal-title":"J Exp Clin Cancer Res"},{"key":"8201_CR30","doi-asserted-by":"crossref","unstructured":"Chen X, Zou Z, Wang Q, Gao W, Zeng S, Ye S, et al. Inhibition of NOS1 promotes the interferon response of melanoma cells. J Transl Med. 2022;20:205.","DOI":"10.1186\/s12967-022-03403-w"},{"key":"8201_CR31","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/nature03464","volume":"434","author":"K Honda","year":"2005","unstructured":"Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature. 2005;434:772\u20137.","journal-title":"Nature"},{"key":"8201_CR32","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.1111\/j.1432-1033.2004.04310.x","volume":"271","author":"H Yang","year":"2004","unstructured":"Yang H, Ma G, Lin CH, Orr M, Wathelet MG. Mechanism for transcriptional synergy between interferon regulatory factor (IRF)-3 and IRF-7 in activation of the interferon-\u03b2 gene promoter. Eur J Biochem. 2004;271:3693\u2013703.","journal-title":"Eur J Biochem"},{"key":"8201_CR33","doi-asserted-by":"publisher","first-page":"8282","DOI":"10.1128\/JVI.00235-07","volume":"81","author":"CH Joo","year":"2007","unstructured":"Joo CH, Shin YC, Gack M, Wu L, Levy D, Jung JU. Inhibition of interferon regulatory factor 7 (IRF7)-mediated interferon signal transduction by the Kaposi\u2019s sarcoma-associated herpesvirus viral IRF homolog vIRF3. J Virol. 2007;81:8282\u201392.","journal-title":"J Virol"},{"key":"8201_CR34","doi-asserted-by":"crossref","unstructured":"Li W, Hofer MJ, Jung SR, Lim SL, Campbell IL. IRF7-dependent type I interferon production induces lethal immune-mediated disease in STAT1 knockout mice infected with lymphocytic choriomeningitis virus. J Virol. 2014;88:7578\u201388.","DOI":"10.1128\/JVI.03117-13"},{"key":"8201_CR35","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1038\/nm.2830","volume":"18","author":"BN Bidwell","year":"2012","unstructured":"Bidwell BN, Slaney CY, Withana NP, Forster S, Cao Y, Loi S, et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med. 2012;18:1224\u201331.","journal-title":"Nat Med"},{"key":"8201_CR36","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1038\/s41388-018-0624-2","volume":"38","author":"Q Lan","year":"2019","unstructured":"Lan Q, Peyvandi S, Duffey N, Huang YT, Barras D, Held W, et al. Type I interferon\/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer. Oncogene. 2019;38:2814\u201329.","journal-title":"Oncogene"},{"key":"8201_CR37","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.bbrc.2006.01.122","volume":"342","author":"A Prakash","year":"2006","unstructured":"Prakash A, Levy DE. Regulation of IRF7 through cell type-specific protein stability. Biochem Biophys Res Commun. 2006;342:50\u20136.","journal-title":"Biochem Biophys Res Commun"},{"key":"8201_CR38","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/gene.2011.21","volume":"12","author":"S Ning","year":"2011","unstructured":"Ning S, Pagano JS, Barber GN. IRF7: activation, regulation, modification and function. Genes Immun. 2011;12:399\u2013414.","journal-title":"Genes Immun"},{"key":"8201_CR39","doi-asserted-by":"crossref","unstructured":"Jiang H, Li Y, Shen M, Liang Y, Qian Y, Dai H, et al. Interferon-\u03b1 promotes MHC I antigen presentation of islet \u03b2 cells through STAT1-IRF7 pathway in type 1 diabetes. Immunology. 2022;166:210\u201321.","DOI":"10.1111\/imm.13468"},{"key":"8201_CR40","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.bbcan.2017.09.005","volume":"1868","author":"K Yarlagadda","year":"2017","unstructured":"Yarlagadda K, Hassani J, Foote IP, Markowitz J. The role of nitric oxide in melanoma. Biochim Biophys Acta Rev Cancer. 2017;1868:500\u20139.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"8201_CR41","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1089\/ars.2012.4563","volume":"19","author":"Z Yang","year":"2013","unstructured":"Yang Z, Misner B, Ji H, Poulos TL, Silverman RB, Meyskens FL, et al. Targeting nitric oxide signaling with nNOS inhibitors as a novel strategy for the therapy and prevention of human melanoma. Antioxid Redox Signal. 2013;19:433\u201347","journal-title":"Antioxid Redox Signal"},{"key":"8201_CR42","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1002\/cncr.22582","volume":"109","author":"C Li","year":"2007","unstructured":"Li C, Hu Z, Liu Z, Wang L, Gershenwald JE, Lee JE, et al. Polymorphisms of the neuronal and inducible nitric oxide synthase genes and the risk of cutaneous melanoma: a case-control study. Cancer. 2007;109:1570\u20138.","journal-title":"Cancer"},{"key":"8201_CR43","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1046\/j.1365-2133.1999.02915.x","volume":"141","author":"B Ahmed","year":"1999","unstructured":"Ahmed B, Van Den Oord JJ. Expression of the neuronal isoform of nitric oxide synthase (nNOS) and its inhibitor, protein inhibitor of nNOS, in pigment cell lesions of the skin. Br J Dermatol. 1999;141:12\u20139.","journal-title":"Br J Dermatol"},{"key":"8201_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-05394-6","volume":"12","author":"S Tong","year":"2022","unstructured":"Tong S, Cinelli MA, El-Sayed NS, Huang H, Patel A, Silverman RB, et al. Inhibition of interferon-gamma-stimulated melanoma progression by targeting neuronal nitric oxide synthase (nNOS). Sci Rep. 2022;12:1701.","journal-title":"Sci Rep"},{"key":"8201_CR45","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1089\/ars.2017.7403","volume":"30","author":"CT Stomberski","year":"2019","unstructured":"Stomberski CT, Hess DT, Stamler JS. Protein S-nitrosylation: determinants of specificity and enzymatic regulation of S-nitrosothiol-based signaling. Antioxid Redox Signal. 2019;30:1331\u201351.","journal-title":"Antioxid Redox Signal"},{"key":"8201_CR46","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1084\/jem.20140654","volume":"212","author":"MS Baig","year":"2015","unstructured":"Baig MS, Zaichick SV, Mao M, De Abreu AL, Bakhshi FR, Hart PC, et al. NOS1-derived nitric oxide promotes NF-\u03baB transcriptional activity through inhibition of suppressor of cytokine signaling-1. J Exp Med. 2015;212:1725\u201338.","journal-title":"J Exp Med"},{"key":"8201_CR47","doi-asserted-by":"crossref","unstructured":"Saini R, Azam Z, Sapra L, Srivastava RK. Neuronal nitric oxide synthase (nNOS) in neutrophils: an insight. Rev Physiol Biochem Pharmacol. 2021;180:49\u201383.","DOI":"10.1007\/112_2021_61"},{"key":"8201_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.106442","volume":"26","author":"DR Coelho","year":"2023","unstructured":"Coelho DR, Palma FR, Paviani V, LaFond KM, Huang Y, Wang D, et al. SOCS1 regulates a subset of NF\u03baB-target genes through direct chromatin binding and defines macrophage functional phenotypes. iScience. 2023;26:106442.","journal-title":"iScience"},{"key":"8201_CR49","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1158\/2326-6066.CIR-22-0387","volume":"11","author":"PP Cunha","year":"2023","unstructured":"Cunha PP, Bargiela D, Minogue E, Krause LCM, Barbieri L, Brombach C, et al. Infiltration of tumors is regulated by T cell\u2013intrinsic nitric oxide synthesis. Cancer Immunol Res. 2023;11:351\u201363.","journal-title":"Cancer Immunol Res"},{"key":"8201_CR50","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1074\/jbc.M111.315598","volume":"287","author":"Z Huang","year":"2012","unstructured":"Huang Z, Hoffmann FW, Fay JD, Hashimoto AC, Chapagain ML, Kaufusi PH, et al. Stimulation of unprimed macrophages with immune complexes triggers a low output of nitric oxide by calcium-dependent neuronal nitric-oxide synthase. J Biol Chem. 2012;287:4492\u2013502.","journal-title":"J Biol Chem"},{"key":"8201_CR51","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/ijc.21767","volume":"119","author":"S Ekmekcioglu","year":"2006","unstructured":"Ekmekcioglu S, Ellerhorst JA, Prieto VG, Johnson MM, Broemeling LD, Grimm EA. Tumor iNOS predicts poor survival for stage III melanoma patients. Int J Cancer. 2006;119:861\u20136.","journal-title":"Int J Cancer"},{"key":"8201_CR52","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.niox.2008.04.009","volume":"19","author":"EA Grimm","year":"2008","unstructured":"Grimm EA, Ellerhorst J, Tang CH, Ekmekcioglu S. Constitutive intracellular production of iNOS and NO in human melanoma: possible role in regulation of growth and resistance to apoptosis. Nitric Oxide. 2008;19:133\u20137.","journal-title":"Nitric Oxide"},{"key":"8201_CR53","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1158\/1078-0432.CCR-09-3123","volume":"16","author":"AG Sikora","year":"2010","unstructured":"Sikora AG, Gelbard A, Davies MA, Sano D, Ekmekcioglu S, Kwon J, et al. Targeted inhibition of inducible nitric oxide synthase inhibits growth of Human melanoma in vivo and synergizes with chemotherapy. Clin Cancer Res. 2010;16:1834\u201344.","journal-title":"Clin Cancer Res"},{"key":"8201_CR54","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1158\/0008-5472.CAN-13-0588","volume":"74","author":"E Lopez-Rivera","year":"2014","unstructured":"Lopez-Rivera E, Jayaraman P, Parikh F, Davies MA, Ekmekcioglu S, Izadmehr S, et al. Inducible nitric oxide synthase drives mTOR pathway activation and proliferation of human melanoma by reversible nitrosylation of TSC2. Cancer Res. 2014;74:1067\u201378.","journal-title":"Cancer Res"},{"key":"8201_CR55","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1111\/j.1582-4934.2011.01375.x","volume":"16","author":"A Barbieri","year":"2012","unstructured":"Barbieri A, Palma G, Rosati A, Giudice A, Falco A, Petrillo A, et al. Role of endothelial nitric oxide synthase (eNOS) in chronic stress-promoted tumour growth. J Cell Mol Med. 2012;16:920\u20136.","journal-title":"J Cell Mol Med"},{"key":"8201_CR56","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.freeradbiomed.2011.02.022","volume":"50","author":"FHM Melo","year":"2011","unstructured":"Melo FHM, Molognoni F, Morais AS, Toricelli M, Mouro MG, Higa EMS, et al. Endothelial nitric oxide synthase uncoupling as a key mediator of melanocyte malignant transformation associated with sustained stress conditions. Free Radic Biol Med. 2011;50:1263\u201373.","journal-title":"Free Radic Biol Med"},{"key":"8201_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/cddiscovery.2017.11","volume":"3","author":"L Zhu","year":"2017","unstructured":"Zhu L, Li L, Zhang Q, Yang X, Zou Z, Hao B, et al. NOS1 S-nitrosylates PTEN and inhibits autophagy in nasopharyngeal carcinoma cells. Cell Death Discov. 2017;3:17011.","journal-title":"Cell Death Discov"},{"key":"8201_CR58","doi-asserted-by":"publisher","first-page":"33047","DOI":"10.18632\/oncotarget.16523","volume":"8","author":"L Li","year":"2017","unstructured":"Li L, Zhu L, Hao B, Gao W, Wang Q, Li K, et al. iNOS-derived nitric oxide promotes glycolysis by inducing pyruvate kinase M2 nuclear translocation in ovarian cancer. Oncotarget. 2017;8:33047\u201363.","journal-title":"Oncotarget"},{"key":"8201_CR59","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.aad0095","volume":"350","author":"EM Van Allen","year":"2015","unstructured":"Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350:207\u201311.","journal-title":"Science"},{"key":"8201_CR60","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165:35\u201344.","journal-title":"Cell"},{"key":"8201_CR61","doi-asserted-by":"crossref","unstructured":"Bogunovic D, O'Neill DW, Belitskaya-Levy I, Vacic V, Yu YL, Adams S, et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci USA. 2009;106.","DOI":"10.1073\/pnas.0905139106"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08201-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08201-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08201-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T17:02:33Z","timestamp":1768410153000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08201-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8201"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08201-y","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"assertion":[{"value":"10 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal experiments in this study were approved by the Medical Ethics Committee of Southern Medical University and conducted in strict accordance with the guidelines from the Ministry of Science and Technology of China.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"33"}}